Nolomirole
Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 90060-42-7
- 화학식: C19H27NO4
- 분자량:333.42
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female rats were given single intraperitoneal injection of Monocrotaline (50 mg/kg) [5].
-
Dosage:0.25 mg/kg
-
Administration:Oral gavage (p.o.), twice a day for 21-25 days after Monocrotaline administration 3 days later, and then evaluated heart hypertrophy and neuroendocrine alterations.
-
Result:Significantly reduced hypertrophy of right atria (0.29 mg/g) and ventricles (1.62 mg/g), plasma levels of ANP and presence of pleural/peritoneal effusions and norepinephrine depletion of right ventricle (from 3.64 nmol /gww to 5.56 nmol/gww).
Chemical Information
-
CAS No. 90060-42-7
-
분자량 333.42
-
화학식 C19H27NO4
-
SMILES
CC(C)C(OC1=C2C(CC(NC)CC2)=CC=C1OC(C(C)C)=O)=O
-
Synonyms
CHF 1035 free base
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. 1. Afzal M. Recent updates on novel therapeutic targets of cardiovascular diseases. Mol Cell Biochem. 2021 Jan; 476(1):145-155. [Content Brief]
[2]. 2. Torp-Pedersen C, et al. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail. 2008 Jan; 10(1):89-95. [Content Brief]
[3]. 3. Tjeerdsma G, et al. Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc Drugs Ther. 2001 Mar; 15(2):139-45. [Content Brief]
[4]. 4. Pasini E, et al. Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan; 49(1):1-5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nolomirole Related Classifications
HY-106973 Related Classifications
Powered by Bioz